Cullen Capital Management’s Quest Diagnostics DGX Stock Holding History

Cullen Capital Management’s Portfolio DGX Stock Details DGX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-1,386	Closed	-$217K	–	278
2022 Q4	$217K	Buy	+1,386	New	+$199K	﹤0.01%	190
2022 Q1	–	Sell	-1,386	Closed	-$240K	–	283
2021 Q4	$240K	Hold	1,386	–	–	﹤0.01%	258
2021 Q3	$201K	Sell	1,386 -1,260	-48%	-$184K	﹤0.01%	255
2021 Q2	$349K	Buy	+2,646	New	+$346K	﹤0.01%	233
2019 Q3	–	Sell	-2,410	Closed	-$245K	–	132
2019 Q2	$245K	Sell	2,410 -3,380	-58%	-$325K	0.01%	123
2019 Q1	$521K	Buy	+5,790	New	+$502K	0.02%	110

Other funds holding DGX

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Victory Capital Management San Antonio, Texas $178B AUM 37.23% 1-Year Est. Return

American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Cullen Capital Management's DGX Position: Q1 2023 in Review

Cullen Capital Management sold out of Quest Diagnostics (DGX) in Q1 2023, closing a stake of 1,386 shares — an estimated $217K sold.

Cullen Capital Management first reported a position in DGX in Q1 2019 and held it in 6 quarters. The position peaked at $521K in Q1 2019. 834 funds tracked by Wall St. Rank hold DGX as of Q1 2023.

Cullen Capital Management reported no remaining Quest Diagnostics position as of Q1 2023 after selling out during the quarter.
Cullen Capital Management sold 1,386 Quest Diagnostics shares in Q1 2023, an estimated $217K.
Cullen Capital Management first reported a position in Quest Diagnostics in Q1 2019 and held it in 6 quarters.
Cullen Capital Management's Quest Diagnostics position peaked at $521K in Q1 2019.
834 funds tracked by Wall St. Rank held Quest Diagnostics as of Q1 2023.

Based on Cullen Capital Management's 13F filing for Q1 2023, filed 15 May 2023.